On Friday, icad inc. (NASDAQ:ICAD)’s shares saw a positive change of +5.81% to close at $4.19 with trading volume of 28.51 thousand shares. After a look at recent stock performance, shares have traded +10.68% off of the 50-day moving average and -3.38% off the 200-day moving average.
iCAD, Inc. (NASDAQ:ICAD) today declared that the company’s Xoft Axxent balloon applicators have received approval from the China Food & Drug Administration (CFDA) for the treatment of early-stage breast cancer. The Xoft Axxent balloon applicators are a key component of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, which is used to perform intraoperative radiation therapy (IORT) in early-stage breast cancer patients who meet specific selection criteria. With this CFDA approval, the complete suite of Xoft System products is now available to clinicians and patients in China.
“A growing number of countries recognize the unique benefits the Xoft System offers to both patients and clinicians in treating a range of cancers,” said Ken Ferry, CEO of iCAD. “In 2015, more than 268,000 women in China were diagnosed with breast cancer, more than 69,000 women died of the disease, and the incidence has been rising rapidly in recent years.1 Regulatory approval of Xoft Axxent balloon applicators in China represents a significant milestone in our continued efforts to bring this innovative, safe and clinically-proven treatment option to women worldwide with early-stage breast cancer.”
Monitoring the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Shares of icad inc. (NASDAQ:ICAD) have been moved at -35.44% separated from the 52-week high of $6.49 and +48.58% away from the 52-week low of $2.82.